Gas-Filled Microvesicles Covalent Antigen Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing gas-filled microvesicle formulations with antigens adhered to their surface are ineffective without ultrasound irradiation, and those with antigically bound to the microvesicle envelope require optimization to enhance their adjuvant effect for immunomodulating treatments.
Innovation Solution
Aqueous suspensions of gas-filled microvesicles with a stabilizing envelope comprising an antigen covalently bound to an amphiphilic component, a phospholipid, and a fatty acid, where the molar ratio of phospholipid to fatty acid is 40/60 or lower, particularly 25/75 or lower, to enhance antigen-specific immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antigen is adhered to the surface of gas-filled microvesicles by static electrical adsorption, then the microvesicles can be prepared, but the formulation is substantially ineffective without ultrasound irradiation
Solution Approach 1:
The patent applies preliminary action by covalently binding the antigen to the microvesicle envelope components (phospholipids or surfactants) during the formulation preparation stage, rather than relying on subsequent ultrasound irradiation to achieve effectiveness. This covalent bonding is established before administration, ensuring the antigen is firmly attached and the formulation is effective upon direct administration without requiring ultrasound activation
Solution Approach 2:
The patent replaces the mechanical/physical system of static electrical adsorption with ultrasound irradiation activation by a chemical bonding system. Instead of using weak electrostatic adsorption that requires mechanical ultrasound energy to become effective, the invention uses covalent chemical bonds to permanently attach the antigen to the envelope, eliminating the need for ultrasound mechanical activation
2Reliability
If the molar ratio of phospholipid to fatty acid is not optimized, then the stabilizing envelope can be formed, but the adjuvant effect is insufficient
Solution Approach 1:
The patent applies parameter changes by optimizing the molar ratio of phospholipid to fatty acid in the stabilizing envelope to at least 40/60 or lower (particularly 25/75 or lower). This specific compositional parameter change enhances the adjuvant effect by creating an envelope with improved properties for antigen presentation and immune cell interaction, while maintaining formulation simplicity through a defined ratio range
3Reliability
If antigen is covalently bound to the microvesicle envelope, then the adjuvant effect is enhanced, but the formulation complexity increases
Solution Approach 1:
The patent applies merging by combining the antigen binding function with the envelope structure itself. The phospholipids or surfactants in the envelope are modified to include covalent binding sites for the antigen, merging the structural envelope component with the antigen-presentation function into a single integrated system, rather than using separate binding mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation significantly increases antigen-specific antibody and T cell responses, promoting effective immunomodulation and vaccine efficacy without the need for ultrasound irradiation, by enhancing the uptake and activation of antigen-presenting cells.
Implementation Method 1
stabilizing envelope comprising (a) an antigen covalently bound to an amphiphilic component forming said envelope, (b) a phospholipid and (c) a fatty acid
Data Source
AI summary
Gas-filled microvesicles comprising an antigen bound thereto and to aqueous suspensions containing said microvesicles, for use in immunomodulating formulations, in particular as a vaccine. The antigen is covalently bound to a component of the microvesicles envelope. The microvesicles of the invention, comprising a molar excess of fatty acids in the stabilizing envelope, are particularly effective in the uptake by antigen-presenting cells, in particular dendritic cells.